Ongoing Trials Aim to Determine Best Regimen for Transplant-Ineligible Patients With MyelomaMarch 1st 2023
Luciano J. Costa, MD, PhD, discussed additional studies evaluating various treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma, aiming to determine the best standard in this population.
GRIFFIN Trial Supports Use of Dara-VRd in Transplant-Eligble Patients With MyelomaFebruary 28th 2023
Luciano J. Costa, MD, PhD, discussed the results from the phase 2 GRIFFIN study, designed to evaluate the combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in transplant-eligible patients with multiple myeloma.
MAIA trial Supports Use of D-Rd in Transplant-Ineligible Patients With MyelomaFebruary 27th 2023
Luciano J. Costa, MD, PhD discussed updating findings from the phase 3 MAIA trial of the triplet combination of daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma.
Genomic Analysis Yields ‘Hypothesis Generating’ Data in Bladder Cancer SubtypeFebruary 26th 2023
An expert from Chase Comprehensive Cancer Center discusses how findings from a genomic analysis of the phase 2 BLASST-1 trial may identify biomarkers of response and resistance to nivolumab/chemotherapy in muscle-invasive bladder cancer.